FDA OKs Certolizumab for Nonradiographic Axial Spondyloarthritis FDA OKs Certolizumab for Nonradiographic Axial Spondyloarthritis

Certolizumab is the first FDA-approved treatment for this type of inflammatory arthritis and fulfills an unmet need for these patients, the FDA says.FDA Approvals
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Rheumatology News Alert Source Type: news